Table 1.
Compound | R’ | R” |
In vitro IC50(µM)a |
||
---|---|---|---|---|---|
CT-L activity | T-L activity | PGPH activity | |||
Bortezomib (Figure 1) |
- | - | 0.009 ± 0.006 | 7.0 ± 0.24 | 0.48 ± 0.021 |
PI-083 | H | 1.0 ± 0.63 | 4.5 ± 1.4 | 4.5 ± 1.2 | |
2s | H | 3.3 ± 0.30 | 8.15 ± 0.84 | 14.3 ± 1.60 | |
2h | H | 3.9 ± 0.50 | 9.25 ± 0.45 | 21.2 ± 0.79 | |
2f | H | 6.4 ± 0.5 | 10.7 ± 0.5 | 13.4 ± 1.1 | |
2d | H | 11.2 ± 3.4 | 13.2 ± 0.2 | 16.7 ± 0.5 | |
13h | OMe | 13.7 ± 0.35 | 24.3 ± 0.04 | 30 ± 1.5 | |
13j | OMe | 15.3 ± 0.89 | 23.3 ± 0.94 | 35 ± 1.90 | |
2b | H | 16.3 ± 6.5 | 20.65 ± 1.45 | 25.6 ± 1.39 | |
13e | H | 17 ± 1 | 24.55 ± 0.55 | 43.5 ± 2.5 | |
2g | H | 19 ± 0.39 | 20.9 ± 0.9 | 50.25 ± 2.25 | |
13d | H | 20.8 ± 0.25 | 24.65 ± 1.0 | 49.25 ± 1.75 | |
13c | H | 20.8 ± 0.3 | 55 ± 2 | > 100 |
Tested in triplicate at least twice.